NCT00535431View on ClinicalTrials.gov

Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics

PHASE2CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

October 31, 2006

Conditions

Allergic Asthma

Interventions

DRUG

AER 001

60 mg (in nebuliser), twice daily for 28 days

DRUG

placebo

Sterile saline nebulised, twice daily for 28 days

Trial Locations (1)

SE1 1YR

Guy's Drug Research Unit, Quintiles, Ltd., London

Sponsors

Lead Sponsor

Aerovance, Inc.

All Listed Sponsors

lead

Aerovance, Inc.

INDUSTRY

NCT00535431 - Effects of AER 001 Administered by Nebulization on Antigen Challenge in Atopic Asthmatics | Biotech Hunter | Biotech Hunter